Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 19, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,249 pence per share; lowest price paid was 1,236.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,163,648,371 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 500,000 repurchased shares. This action increased the proportion of Treasury shares held by the Company to 8.72% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of Treasury shares held (493,224,284) against subsequent filings to track ongoing buyback activity.
- Confirm the denominator for voting rights calculations (5,163,648,371 shares) when assessing shareholder notification thresholds.
- Review the Annual General Meeting minutes from May 6, 2010, to understand the full scope of the share repurchase authority utilized.